- Home
- WHWK vs ADAP Comparison
WHWK vs ADAP Comparison
Compare WHWK & ADAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WHWK
- ADAP
- Stock Information
- Founded
- WHWK 2007
- ADAP 2008
- Country
- WHWK United States
- ADAP United Kingdom
- Employees
- WHWK N/A
- ADAP N/A
- Industry
- WHWK Biotechnology: Pharmaceutical Preparations
- ADAP Biotechnology: Pharmaceutical Preparations
- Sector
- WHWK Health Care
- ADAP Health Care
- Exchange
- WHWK Nasdaq
- ADAP Nasdaq
- Market Cap
- WHWK 87.6M
- ADAP 75.5M
- IPO Year
- WHWK N/A
- ADAP 2015
- Fundamental
- Price
- WHWK $1.94
- ADAP $0.27
- Analyst Decision
- WHWK
- ADAP Buy
- Analyst Count
- WHWK 0
- ADAP 6
- Target Price
- WHWK N/A
- ADAP $1.35
- AVG Volume (30 Days)
- WHWK 148.4K
- ADAP 576.6K
- Earning Date
- WHWK 08-15-2025
- ADAP 08-11-2025
- Dividend Yield
- WHWK N/A
- ADAP N/A
- EPS Growth
- WHWK N/A
- ADAP N/A
- EPS
- WHWK 0.91
- ADAP N/A
- Revenue
- WHWK $27,775,000.00
- ADAP $179,639,000.00
- Revenue This Year
- WHWK $49.83
- ADAP N/A
- Revenue Next Year
- WHWK N/A
- ADAP $35.48
- P/E Ratio
- WHWK $2.24
- ADAP N/A
- Revenue Growth
- WHWK 16.51
- ADAP 878.53
- 52 Week Low
- WHWK $1.21
- ADAP $0.20
- 52 Week High
- WHWK $3.81
- ADAP $1.48
- Technical
- Relative Strength Index (RSI)
- WHWK N/A
- ADAP 54.99
- Support Level
- WHWK N/A
- ADAP $0.23
- Resistance Level
- WHWK N/A
- ADAP $0.29
- Average True Range (ATR)
- WHWK 0.00
- ADAP 0.02
- MACD
- WHWK 0.00
- ADAP 0.00
- Stochastic Oscillator
- WHWK 0.00
- ADAP 77.69
About WHWK Whitehawk Therapeutics Inc. Common Stock
Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.